Model Medicines announces AI-driven drug discovery partnership with Sanford Burnham Prebys
LA JOLLA, Calif., March 23, 2021 /PRNewswire/ --Model Medicines, an AI drug discovery software company, today announced they have entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.
- LA JOLLA, Calif., March 23, 2021 /PRNewswire/ --Model Medicines, an AI drug discovery software company, today announced they have entered into a multi-target collaboration agreement with Sanford Burnham Prebys Medical Discovery Institute to identify and develop drugs for novel antiviral targets.
- The collaboration leverages Model Medicines' ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, in conjunction with Sanford Burnham Prebys' identification of novel antiviral targets and deep scientific expertise, to discover and develop new treatments for SARS-CoV-2 and other infectious diseases.
- Model Medicines has created an infectious disease specific version of their ActivPred AI Drug Discovery Platform that focuses exclusively on identifying safe and effective, non-obvious therapeutics with activity against the novel biological targets identified by Sanford Burnham Prebys.
- Model Medicines is transforming drug discovery by leveraging the historical compendium of drug development data, a drug and disease agnostic discovery platform, and unbiased AI to create Phase II/III ready drug candidates in months rather than years.